Dr. Reddy's Laboratories will not be precluded post regulatory approval from launching its proposed biosimilar to Orencia (abatacept), under the terms of a broad worldwide licensing agreement the Indian firm has just struck with clinical-stage biotech firm Coya Therapeutics.
The Texas-based firm has in-licensed Reddy’s proposed abatacept biosimilar for the development of its proposed ‘COYA 302’ combination product for